Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder typified by occlusion
of the pulmonary arterioles owing to endothelial dysfunction and uncontrolled proliferation of …

2022 ESC/ERS pulmonary hypertension guidelines incorporate changes and adaptations
focusing on clinical management https://bit. ly/3QtUvb4

Since the 1st World Symposium on Pulmonary Hypertension (WSPH) in 1973, pulmonary
hypertension (PH) has been arbitrarily defined as mean pulmonary arterial pressure …

The pulmonary circulation is a low-resistance, low-pressure, and high-compliance system
that allows the lungs to receive the entire cardiac output. Pulmonary arterial pressure is a …

Background Group 1 pulmonary arterial hypertension (PAH) is a rare disease with high
mortality despite recent therapeutic advances. Pathogenic remodeling of pulmonary …

Pulmonary arterial hypertension (PAH) is a rare disease that can be caused by (likely)
pathogenic germline genomic variants. In addition to the most prevalent disease gene …

Genome-wide association studies have identified 240 independent loci associated with type
2 diabetes (T2D) risk, but this knowledge has not advanced precision medicine. In contrast …

Potassium (K+) ion channel activity is an important determinant of vascular tone by
regulating cell membrane potential (MP). Activation of K+ channels leads to membrane …

Background Pulmonary arterial hypertension (PAH) is a lethal vasculopathy characterized
by pathogenic remodeling of pulmonary arterioles leading to increased pulmonary …